Objective
Antiretroviral therapy (ART) has been implicated in bone loss in HIV. The role of inflammation and vitamin D is unclear and better investigated in ART-naïve individuals.
Design and Methods
This is a 48-week, prospective, cohort study to compare baseline and change in hip and spine bone mineral density (BMD) measured by dual energy Xray absorptiometry (DXA) in HIV-infected, ART-naïve adults and healthy controls matched by age, sex, and race. We also studied associations between bone loss and inflammation markers and plasma 25-hydroxyvitamin D (25(OH)D) using logistic regression.
Results
47 HIV-infected adults and 41 controls were included. Baseline 25(OH)D, BMD at total hip, trochanter, and spine, and prevalence of osteopenia and osteoporosis were similar between groups. In the HIV-infected group, total hip and trochanter, but not spine, BMD decreased over 48 weeks (hip −0.005 (−0.026-0.008)g/cm2, p=0.02 within-group; trochanter −0.013 (−0.03-0.003), p<0.01). BMD did not change at any site within controls. The HIV-infected group was more likely to have bone loss at the trochanter (p=0.03). This risk persisted after adjustment for age, sex, race, BMI, smoking, and hepatitis C (OR 4 (95% CI 1.2-15.8)). In the HIV-infected group, higher IL-6 concentrations (p=0.04) and Caucasian race (p<0.01) were independently associated with progression to osteopenia or osteoporosis, but not 25(OH)D levels.
Conclusion
BMD at the total hip and trochanter sites decreased in the HIV-infected, ART-naïve adults, but not controls, over this 48-week study. Higher serum IL-6 concentrations were associated with progression to osteopenia or osteoporosis status in the HIV-infected group.